{"id":22994,"date":"2024-11-06T07:49:00","date_gmt":"2024-11-05T23:49:00","guid":{"rendered":"https:\/\/www.franchise.com.hk\/%e3%80%902024-ash%e3%80%91-%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5bcl-2%e6%8a%91%e5%88%b6%e5%8a%91apg-2575%e4%b8%89%e9%a0%85%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%90%ab1\/22994"},"modified":"2024-11-06T07:49:00","modified_gmt":"2024-11-05T23:49:00","slug":"%e3%80%902024-ash%e3%80%91-%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5bcl-2%e6%8a%91%e5%88%b6%e5%8a%91apg-2575%e4%b8%89%e9%a0%85%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%90%ab1","status":"publish","type":"post","link":"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91-%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5bcl-2%e6%8a%91%e5%88%b6%e5%8a%91apg-2575%e4%b8%89%e9%a0%85%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%90%ab1\/22994","title":{"rendered":"\u30102024 ASH\u3011 \u4e9e\u76db\u91ab\u85e5Bcl-2\u6291\u5236\u5291APG-2575\u4e09\u9805\u81e8\u5e8a\u7814\u7a76\u5165\u9078\uff0c\u542b1\u9805\u53e3\u982d\u5831\u544a\uff01"},"content":{"rendered":"<p><span class=\"legendSpanClass\">\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde<\/span><span class=\"legendSpanClass\">2024\u5e7411\u67086\u65e5<\/span> \/\u7f8e\u901a\u793e\/ &#8212;\u00a0\u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u4f48\uff0c\u516c\u53f8\u91cd\u9ede\u54c1\u7a2eAPG-2575\uff08Lisaftoclax\uff09\u5171\u67093\u9805\u81e8\u5e8a\u9032\u5c55\u7372\u9078\u7b2c66\u5c46\u7f8e\u570b\u8840\u6db2\u5b78\u6703\uff08American Society of Hematology\uff0cASH\uff09\u5e74\u6703\uff0c\u5176\u4e2d\u4e00\u9805\u7372\u53e3\u982d\u5831\u544a\u3002\u9019\u662f\u8a72\u54c1\u7a2e\u7684\u81e8\u5e8a\u9032\u5c55\u9023\u7e8c\u7b2c3\u5e74\u5165\u9078ASH\u5e74\u6703\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u4eca\u5e74\u516c\u53f8\u56db\u500b\u54c1\u7a2e\uff08\u8010\u7acb\u514b\u3001APG-2575\u3001APG-2449\u3001APG-5918\uff09\u6709\u591a\u9805\u81e8\u5e8a\u548c\u81e8\u5e8a\u524d\u9032\u5c55\u5165\u9078ASH\u5e74\u6703\u5c55\u793a\u53ca\u5831\u544a\uff0c\u4e26\u7372\u5169\u9805\u53e3\u982d\u5831\u544a\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p>APG-2575\uff08Lisaftoclax\uff09\u662f\u4e9e\u76db\u91ab\u85e5\u81ea\u4e3b\u7814\u767c\u7684\u3001\u5177\u5168\u7403best-in-class\u6f5b\u529b\u7684\u65b0\u578b\u53e3\u670dBcl-2\u9078\u64c7\u6027\u6291\u5236\u5291\uff0c\u5728\u591a\u7a2e\u8840\u6db2\u816b\u7624\u548c\u5be6\u9ad4\u7624\u6cbb\u7642\u9818\u57df\u5177\u5099\u5ee3\u95ca\u7684\u6cbb\u7642\u6f5b\u529b\u3002\u4e9e\u76db\u91ab\u85e5\u5c07\u5728\u6b64\u6b21ASH\u5e74\u6703\u4e0a\uff0c\u53e3\u982d\u5831\u544a\u8a72\u54c1\u7a2e\u6cbb\u7642\u5fa9\u767c\/\u96e3\u6cbb\uff08R\/R\uff09\u591a\u767c\u6027\u9aa8\u9ad3\u7624(MM\uff09\u6216\u514d\u75ab\u7403\u86cb\u767d\u8f15\u93c8\uff08AL\uff09\u6fb1\u7c89\u6a23\u8b8a\u6027\u60a3\u8005\u7684I\/II\u671f\u81e8\u5e8a\u7814\u7a76\u6700\u65b0\u9032\u5c55\u3002\u6b64\u5916\uff0c\u5176\u806f\u5408\u6cbb\u7642\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\uff08MDS\uff09\u60a3\u8005\u7684\u6700\u65b0\u6578\u64da\u4e5f\u5c07\u4ee5\u58c1\u5831\u5c55\u793a\u5f62\u5f0f\u516c\u4f48\u3002<\/p>\n<p>\u4e00\u5e74\u4e00\u5ea6\u7684ASH\u5e74\u6703\u662f\u5168\u7403\u8840\u6db2\u5b78\u9818\u57df\u898f\u6a21\u6700\u5927\u7684\u570b\u969b\u5b78\u8853\u76db\u6703\u4e4b\u4e00\uff0c\u5168\u9762\u6db5\u84cb\u4e86\u8840\u6db2\u75be\u75c5\u7684\u75c5\u56e0\u7814\u7a76\u548c\u6cbb\u7642\u7814\u7a76\u3002\u7b2c66\u5c46ASH\u5e74\u6703\u5c07\u65bc\u7576\u5730\u6642\u95932024\u5e7412\u67087\u65e5\u81f310\u65e5\u9593\u5728\u7f8e\u570b\u8056\u5730\u4e9e\u54e5\u4ee5\u7dda\u4e0b\u7d50\u5408\u7dda\u4e0a\u7684\u5f62\u5f0f\u8209\u884c\u3002<\/p>\n<p>\u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300cAPG-2575\uff08Lisaftoclax\uff09\u662f\u5168\u7403\u7b2c\u4e8c\u500b\u3001\u570b\u5167\u9996\u500b\u770b\u5230\u660e\u78ba\u7642\u6548\u3001\u4e26\u9032\u5165\u95dc\u9375\u8a3b\u518a\u81e8\u5e8a\u968e\u6bb5\u7684Bcl-2\u6291\u5236\u5291\uff0c\u76ee\u524d\u6b63\u5728\u958b\u5c55\u56db\u9805\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\u3002\u8a72\u54c1\u7a2e\u7684\u591a\u500b\u81e8\u5e8a\u9032\u5c55\u518d\u6b21\u5165\u9078ASH\u5e74\u6703\u5831\u544a\uff0c\u9032\u4e00\u6b65\u9ad4\u73feAPG-2575\uff08Lisaftoclax\uff09\u9019\u4e00\u5168\u7403Best-in-class\u6f5b\u529b\u54c1\u7a2e\u5728\u8840\u6db2\u816b\u7624\u9818\u57df\u5f37\u52c1\u7684\u6cbb\u7642\u6f5b\u529b\u3002\u6b64\u5916\uff0c\u4eca\u5e74\uff0c\u516c\u53f8\u56db\u500b\u91cd\u9ede\u54c1\u7a2e\u6709\u591a\u9805\u9032\u5c55\u5165\u9078ASH\u5e74\u6703\u5c55\u793a\u53ca\u5831\u544a\uff0c\u5145\u5206\u986f\u73fe\u4e86\u516c\u53f8\u7684\u5168\u7403\u5275\u65b0\u548c\u958b\u767c\u5be6\u529b\u3002\u6211\u5011\u671f\u5f85\u5728\u5f8c\u7e8c\u6703\u8b70\u671f\u9593\u8207\u5927\u5bb6\u5206\u4eab\u76f8\u95dc\u7814\u7a76\u7684\u8a73\u5be6\u6578\u64da\u3002\u672a\u4f86\uff0c\u4e9e\u76db\u91ab\u85e5\u5c07\u9032\u4e00\u6b65\u52a0\u901f\u63a8\u9032\u81e8\u5e8a\u958b\u767c\uff0c\u65e9\u65e5\u70ba\u60a3\u8005\u5e36\u4f86\u66f4\u591a\u6cbb\u7642\u9078\u64c7\u3002\u300d<\/p>\n<p>ASH 2024\u4e9e\u76db\u91ab\u85e5\u7522\u54c1\u76f8\u95dc\u7814\u7a76\u4e00\u89bd\uff1a<\/p>\n<div>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5c55\u793a\u5f62\u5f0f<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u54c1\u7a2e<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u6458\u8981\u6a19\u984c<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u7de8\u865f<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u53e3\u982d\u5831\u544a<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\uff08HQP1351\uff09<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Olverembatinib as Second-Line (2L) Therapy in Patients <br \/>(pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-<br \/>CML)<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c\u7528\u65bc\u6162\u6027\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CP-CML\uff09\u60a3<br \/>\u8005\u7684\u4e8c\u7dda\u6cbb\u7642<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">480<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">APG-2575<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\uff08Lisaftoclax\uff09<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Lisaftoclax (APG-2575) Combined with Novel Therapeutic <br \/>Regimens in Patients (pts) with Relapsed or Refractory <br \/>Multiple Myeloma (R\/R MM) or Immunoglobulin Light-<br \/>Chain (AL) Amyloidosis<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Lisaftoclax\uff08APG-2575\uff09\u806f\u5408\u65b0\u578b\u6cbb\u7642\u65b9\u6848\u7528\u65bc\u5fa9\u767c\/\u96e3<br \/>\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff08R\/R MM\uff09\u6216\u514d\u75ab\u7403\u86cb\u767d\u8f15\u93c8<br \/>\uff08AL\uff09\u6fb1\u7c89\u6a23\u8b8a\u6027\u60a3\u8005\uff08pts\uff09<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">1022<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u58c1\u5831\u5c55\u793a<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\uff08HQP1351\uff09<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Olverembatinib (HQP1351) Overcomes <br \/>Resistance\/Intolerance to Asciminib and Ponatinib in <br \/>Patients (pts) with Heavily Pretreated Chronic-Phase <br \/>Chronic Myeloid Leukemia (CP CML): A 1.5-Year Follow-up <br \/>Update with Comprehensive Exposure-Response (E-R) <br \/>Analyses<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u53ef\u514b\u670d\u7d93\u6df1\u5ea6\u6cbb\u7642\u7684\u6162\u6027\u671f\u6162<br \/>\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CP CML\uff09\u60a3\u8005\u5c0dAsciminib\u548c<br \/>Ponatinib\u7684\u8010\u85e5\/\u4e0d\u8010\u53d7\uff1a\u4f86\u81ea1.5\u5e74\u96a8\u8a2a\u7684\u6700\u65b0\u6578\u64da\u53ca<br \/>\u7d9c\u5408\u66b4\u9732-\u53cd\u61c9\uff08E-R\uff09\u5206\u6790<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">3151<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">APG-2575<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\uff08Lisaftoclax\uff09<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Lisaftoclax (APG-2575) Demonstrates Activity and Safety <br \/>When Given with Accelerated Ramp-up and then Combined <br \/>with Acalabrutinib or Rituximab in Patients (pts) with <br \/>Chronic Lymphocytic Leukemia\/Small Lymphocytic <br \/>Lymphoma (CLL\/SLL), Including Those with Prior Exposure <br \/>to Venetoclax<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Lisaftoclax\uff08APG-2575\uff09\u5728\u5feb\u901f\u5291\u91cf\u905e\u589e\u7d66\u85e5\u5f8c\u8207\u963f\u53ef\u66ff<br \/>\u5c3c\u6216\u5229\u59a5\u6614\u55ae\u6297\u806f\u5408\u6cbb\u7642\u5728\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb<br \/>\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u4e2d\u7684\u5b89\u5168\u6027\u548c\u6297\u816b\u7624\u6d3b<br \/>\u6027\uff0c\u5305\u62ec\u65e2\u5f80\u63a5\u53d7\u7dad\u5948\u514b\u62c9\u6cbb\u7642\u7684\u60a3\u8005<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">4614<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">APG-2575<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\uff08Lisaftoclax\uff09<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in <br \/>Combination with Azacitidine in Treatment of Patients with <br \/>Myelodysplastic Syndrome (MDS)<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u65b0\u578bBcl-2\u6291\u5236\u5291Lisaftoclax\uff08APG-2575\uff09\u806f\u5408\u963f\u624e\u80de\u7518\u6cbb\u7642\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\uff08MDS\uff09<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">3202<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">+<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">APG-2575<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Safety and Efficacy of Olverembatinib (HQP1351) Combined <br \/>with Lisaftoclax (APG-2575) in Children and Adolescents <br \/>with Relapsed\/Refractory Philadelphia Chromosome\u2013<br \/>Positive Acute Lymphoblastic Leukemia (R\/R Ph+ ALL): First <br \/>Report from a Phase 1 Study<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u806f\u5408Lisaftoclax\uff08APG-2575\uff09<br \/>\u6cbb\u7642\u5fa9\u767c\/\u96e3\u6cbb\u6027\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5<br \/>\uff08R\/R Ph+ ALL\uff09\u5152\u7ae5\u53ca\u9752\u5c11\u5e74\u60a3\u8005\u7684\u5b89\u5168\u6027\u548c\u7642\u6027\uff1a\u4e00<br \/>\u9805I\u671f\u81e8\u5e8a\u7814\u7a76\u7684\u9996\u6b21\u5831\u544a\u3002<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">1443<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\uff08HQP1351\uff09<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">A Phase 2 Study of Olverembatinib for the Treatment of <br \/>Myeloid\/Lymphoid Neoplasms with FGFR1 <br \/>Rearrangement<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u4e00\u9805\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u651c\u5e36FGFR1\u57fa\u56e0\u91cd\u6392\u7684\u9ad3\u7d30<br \/>\u80de\/\u6dcb\u5df4\u7d30\u80de\u816b\u7624\u7684II\u671f\u81e8\u5e8a\u7814\u7a76<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">1781<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\uff08HQP1351\uff09<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Olverembatinib 30 Mg Versus 40 Mg Every Other Day <br \/>(QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) <br \/>Resistant or Intolerant Chronic-Phase Chronic Myeloid <br \/>Leukemia (CML-CP): A Multi-Center Propensity Score-<br \/>Matched Analysis<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u9694\u5929\u4e00\u6b21\uff08QOD\uff0930mg\u8f03QOD 40mg\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb<br \/>\u7642\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08TKI\uff09\u8010\u85e5\u6216\u4e0d\u8010\u53d7\u7684\u6162\u6027\u671f<br \/>\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CML-CP\uff09\u60a3\u8005\uff1a\u4e00\u9805\u591a\u4e2d\u5fc3\u50be\u5411<br \/>\u5f97\u5206\u5339\u914d\u5206\u6790<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">4529<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\uff08HQP1351\uff09<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Combination of Olverembatinib and VP Regimen for <br \/>Newly Diagnosed Adult Philadelphia Chromosome-<br \/>Positive Acute Lymphoblastic Leukemia<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408VP\u65b9\u6848\u6cbb\u7642\u65b0\u8a3a\u65b7\u7684\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d<br \/>\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u6210\u4eba\u60a3\u8005<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">1449<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\uff08HQP1351\uff09<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Olverembatinib-Therapy in Patients with Accelerated-<br \/>Phase Chronic Myeloid Leukaemia: A Multi-Centre <br \/>Retrospective Study from China<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u52a0\u901f\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff1a\u4e00\u9805\u5728\u4e2d<br \/>\u570b\u958b\u5c55\u7684\u591a\u4e2d\u5fc3\u56de\u9867\u6027\u7814\u7a76<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">1767<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\uff08HQP1351\uff09<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Olverembatinib-Based Therapy in Patients with <br \/>Philadelphia Chromosome-Positive Acute Leukemia: A <br \/>Multi-Centre Retrospective Study from China<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u57fa\u65bc\u5967\u96f7\u5df4\u66ff\u5c3c\u7642\u6cd5\u6cbb\u7642\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u767d\u8840<br \/>\u75c5\uff1a\u4e00\u9805\u5728\u4e2d\u570b\u958b\u5c55\u7684\u591a\u4e2d\u5fc3\u56de\u9867\u6027\u7814\u7a76<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">4528<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">APG-2575<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">+<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">APG-2449<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">APG-2449, a Novel Focal Adhesion Kinase (FAK) Inhibitor, <br \/>Exhibits Antileukemic Activity and Enhances Lisaftoclax <br \/>(APG-2575)-Induced Apoptosis in Acute Myeloid Leukemia <br \/>(AML)<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u65b0\u578b\u5c40\u7076\u6027\u9ecf\u9644\u6fc0\u9176\uff08FAK\uff09\u6291\u5236\u5291APG-2449\u5728\u6025\u6027\u9ad3<br \/>\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u4e2d\u986f\u793a\u4e86\u6297\u767d\u8840\u75c5\u6d3b\u6027\u4e26\u5f37\u5316\u4e86\u7531<br \/>Lisaftoclax\uff08APG-2575\uff09\u8a98\u5c0e\u7684\u7d30\u80de\u51cb\u4ea1<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">4150<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">APG-5918<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Embryonic Ectoderm Development (EED) Inhibitor APG-<br \/>5918 Demonstrates Robust Antitumor Activity in Preclinical <br \/>Models of T-Cell Lymphomas (TCLs)<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u80da\u80ce\u5916\u80da\u5c64\u767c\u80b2\u86cb\u767d\uff08EED\uff09\u6291\u5236\u5291APG-5918\u5728T\u7d30\u80de<br \/>\u6dcb\u5df4\u7624\uff08TCL\uff09\u81e8\u5e8a\u524d\u6a21\u578b\u4e2d\u986f\u793a\u4e86\u5f37\u6548\u7684\u6297\u816b\u7624\u6d3b\u6027<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">1415<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5728\u7dda\u767c\u4f48<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">+<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">APG-2575<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Olverembatinib (HQP1351) in Combination with Lisaftoclax <br \/>Overcomes Venetoclax Resistance in Preclinical Model of <br \/>Acute Myeloid Leukemia (AML)<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u806f\u5408Lisaftoclax\uff08APG-2575\uff09<br \/>\u53ef\u5728\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u81e8\u5e8a\u524d\u6a21\u578b\u4e2d\u514b\u670d<br \/>Venetoclax\u8010\u85e5<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">5777<\/span><\/p>\n<\/div>\n<p>APG-2575\uff08Lisaftoclax\uff09\u5165\u90782024 ASH\u5e74\u6703\u7684\u7814\u7a76\u6458\u8981\u5982\u4e0b\uff1a\uff08\u8010\u7acb\u514b\u00ae\u5165\u9078ASH\u5e74\u6703\u7684\u6458\u8981\u8a73\u7d30\u4fe1\u606f\u53c3\u898b\u540c\u671f\u767c\u4f48\u7684\u53e6\u4e00\u7bc7\u65b0\u805e\u7a3f\uff09<\/p>\n<p>\u53e3\u982d\u5831\u544a<\/p>\n<p>Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (pts) with Relapsed or Refractory Multiple Myeloma (R\/R MM) or Immunoglobulin Light- Chain (AL) Amyloidosis<br \/>Lisaftoclax\uff08APG-2575\uff09\u806f\u5408\u65b0\u578b\u6cbb\u7642\u65b9\u6848\u7528\u65bc\u5fa9\u767c\/\u96e3\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff08R\/R MM\uff09\u6216\u514d\u75ab\u7403\u86cb\u767d\u8f15\u93c8\uff08AL\uff09\u6fb1\u7c89\u6a23\u8b8a\u6027\u60a3\u8005\uff08pts\uff09<\/p>\n<p>\u5c55\u793a\u5f62\u5f0f\uff1a\u53e3\u982d\u5831\u544a<\/p>\n<p>\u6458\u8981\u7de8\u865f\uff1a1022<\/p>\n<p>\u5206\u6703\u5834\uff1a654. \u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff1a\u85e5\u7269\u7642\u6cd5\uff1a\u672a\u4f86\u5c55\u671b\uff1a\u7528\u65bc\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684\u65b0\u85e5\u548c\u806f\u5408\u7642\u6cd5<\/p>\n<p>\u5831\u544a\u6642\u9593\uff1a<\/p>\n<p>2024\u5e7412\u67089\u65e5\uff0c\u661f\u671f\u4e00\uff0c\u4e0b\u534816:45\uff08\u7f8e\u570b\u897f\u90e8\u6642\u9593\uff09<br \/>2024\u5e7412\u670810\u65e5\uff0c\u661f\u671f\u4e8c\uff0c\u4e0a\u53488:45\uff08\u5317\u4eac\u6642\u9593\uff09<\/p>\n<p>\u7b2c\u4e00\u4f5c\u8005\uff1a\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\u00a0Sikander Ailawadhi\u6559\u6388<\/p>\n<p>\u6838\u5fc3\u8981\u9ede\uff1a<\/p>\n<p>\u7814\u7a76\u80cc\u666f\uff1a<\/p>\n<p>MM\u7684\u7279\u5fb5\u662f\u7570\u5e38\u6f3f\u7d30\u80de\u514b\u9686\u589e\u6b96\uff0c\u5c0e\u81f4\u7834\u58de\u6027\u9aa8\u75c5\u8b8a\u3001\u814e\u640d\u50b7\u3001\u8ca7\u8840\u548c\u9ad8\u9223\u8840\u75c7\u3002MM\u7684\u6cbb\u7642\u65b9\u6cd5\u5305\u62ec\u4f7f\u7528\u514d\u75ab\u8abf\u7bc0\u5291\u3001\u86cb\u767d\u9176\u9ad4\u6291\u5236\u5291\u548c\u6297CD38\u55ae\u514b\u9686\u6297\u9ad4\uff0c\u4ee5\u9054\u5230\u75be\u75c5\u7de9\u89e3\u7684\u76ee\u7684\u3002   AL\u6fb1\u7c89\u6a23\u8b8a\u6027\u662f\u4e00\u7a2e\u7d30\u80de\u5916\u932f\u8aa4\u6298\u758a\u86cb\u767d\u7570\u5e38\u6c89\u7a4d\u65bc\u5404\u5668\u5b98\u4e26\u9020\u6210\u640d\u5bb3\u7684\u75be\u75c5\uff0c\u4e3b\u8981\u6cbb\u7642\u7b56\u7565\u662f\u63a8\u9072\u5668\u5b98\u529f\u80fd\u969c\u7919\u7684\u6642\u9593\u6216\u9006\u8f49\u5668\u5b98\u529f\u80fd\u969c\u7919\u3002\u7136\u800c\uff0c\u8a31\u591a\u60a3\u8005\u5728\u63a5\u53d7\u6a19\u6e96\u7684\u4e09\u806f\u6216\u56db\u806f\u7642\u6cd5\u5f8c\u6703\u51fa\u73fe\u5fa9\u767c\uff0c\u9019\u5c31\u9700\u8981\u63a1\u7528\u5177\u6709\u65b0\u4f5c\u7528\u6a5f\u5236\u7684\u5176\u4ed6\u7642\u6cd5\u3002   APG-2575\uff08Lisaftoclax\uff09\u662f\u4e00\u7a2e\u65b0\u578bBcl-2\u6291\u5236\u5291\uff0c\u5728\u524d\u671f\u7814\u7a76\u4e2d\u986f\u793a\u51fa\u5f88\u5f37\u7684\u6297\u816b\u7624\u6d3b\u6027\u3002\u5728\u6b64\uff0c\u6211\u5011\u5831\u544a\u4e86APG-2575\uff08Lisaftoclax\uff09\u806f\u5408\u65b0\u578b\u6cbb\u7642\u65b9\u6848\u5728R\/R MM\u6216R\/R AL\u6fb1\u7c89\u6a23\u8b8a\u6027\u60a3\u8005\u4e2d\u7684\u81e8\u5e8a\u8a66\u9a57\u6578\u64da\u3002  <\/p>\n<p>\u7814\u7a76\u4ecb\u7d39\uff1a\u9019\u662f\u4e00\u9805\u591a\u4e2d\u5fc3\u3001\u958b\u653e\u6027I\/II\u671f\u81e8\u5e8a\u7814\u7a76\u3002<\/p>\n<p>\u5165\u7d44\u60a3\u8005\u548c\u7814\u7a76\u65b9\u6cd5\uff1a<\/p>\n<p>\u7b26\u5408\u689d\u4ef6\u7684\u60a3\u8005\u9700 ECOG\u8a55\u5206 \u2264 2\uff0c\u65e2\u5f80\u63a5\u53d7\u904e\u2265 1\u7a2e\u6cbb\u7642\uff0c\u4e14\u5668\u5b98\u529f\u80fd\u6b63\u5e38\u3002R\/R AL\u6fb1\u7c89\u6a23\u8b8a\u6027\u60a3\u8005\u5df2\u78ba\u8a3a\u6709\u75c7\u72c0\u7684\u5668\u5b98\u53d7\u7d2f\u3002APG-2575\uff08Lisaftoclax\uff09\u6bcf\u65e5\u53e3\u670d\uff0c\u4ee528\u5929\u70ba\u9031\u671f\u91cd\u8907\u7d66\u85e5\u3002\u6cca\u99ac\u5ea6\u80fa\u3001\u9054\u96f7\u59a5\u5c24\u55ae\u6297\u548c\u4f86\u90a3\u5ea6\u80fa\u6309\u8aaa\u660e\u66f8\u7528\u6cd5\u7d66\u85e5\u3002\u5730\u585e\u7c73\u677e 40 mg\uff0820 mg\uff0c\u5e74\u9f61&gt;75\u6b72\uff09\u572828\u5929\u9031\u671f\u7684\u7b2c1\u30018\u300115\u548c22\u5929\u7d66\u85e5\u3002   \u9019\u9805\u7814\u7a76\u8a55\u4f30\u4e86APG-2575\uff08Lisaftoclax\uff09\u806f\u5408\u6cca\u99ac\u5ea6\u80fa\u548c\u5730\u585e\u7c73\u677e\u6cbb\u7642R\/R MM\u60a3\u8005\uff08Pd\uff1b\u6cbb\u7642\u7d44A\uff09\uff1b\u806f\u5408\u9054\u96f7\u59a5\u5c24\u55ae\u6297\u3001\u4f86\u90a3\u5ea6\u80fa\u548c\u5730\u585e\u7c73\u677e\u6cbb\u7642R\/R MM\u60a3\u8005\uff08DRd\uff1b\u6cbb\u7642\u7d44B\uff09\uff1b\u806f\u5408Pd\u65b9\u6848\u6cbb\u7642R\/R AL\u6fb1\u7c89\u6a23\u8b8a\u6027\uff08\u6cbb\u7642\u7d44C\uff09\u60a3\u8005\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u3002   \u622a\u81f32024\u5e745\u670829\u65e5\uff0c\u5171\u670952\u4f8b\u60a3\u8005\u5165\u7d44\uff0c\u5176\u4e2d\u5305\u62ec42\u4f8bR\/R MM\u60a3\u8005\u548c10\u4f8bAL\u6fb1\u7c89\u6a23\u8b8a\u6027\u60a3\u8005\u3002\u6240\u6709\u60a3\u8005\u7684\u5e74\u9f61\u4e2d\u4f4d\u6578\uff08\u7bc4\u570d\uff09\u70ba 69.5\uff0824-88\uff09\u6b72\uff0c\u5176\u4e2d 63.5%\u70ba\u7537\u6027\uff0c63.5%\u7684\u60a3\u8005\u5e74\u9f61\u2265 65 \u6b72\u3002\u5165\u9078\u60a3\u8005\u65e2\u5f80\u5747\u63a5\u53d7\u904e\u6df1\u5ea6\u6cbb\u7642\uff0c\u65e2\u5f80\u6cbb\u7642\u7dda\u6578\u7684\u4e2d\u4f4d\u6578\uff08\u7bc4\u570d\uff09\u70ba3\uff081-19\uff09\u7dda\u3002   \u5728A\u7d44\uff08n=35\uff09\u4e2d\uff0cAPG-2575\uff08Lisaftoclax\uff09\u6309\u6307\u5b9a\u5291\u91cf\u53e3\u670d\u7d66\u85e5\uff1a400mg\uff083\u4f8b\uff09\u3001600mg\uff084\u4f8b\uff09\u3001800mg\uff0815\u4f8b\uff09\u30011,000mg\uff087\u4f8b\uff09\u548c1,200mg\uff086\u4f8b\uff09\u3002\u5728B\u7d44\uff08n=7\uff09\u4e2d\uff0c\u6240\u6709\u60a3\u8005\u90fd\u63a5\u53d7\u4e86600mg APG-2575\uff08Lisaftoclax\uff09\u7684\u6cbb\u7642\u3002\u5728 C \u7d44\uff08n=10\uff09\u4e2d\uff0c\u7d66\u85e5\u5291\u91cf\u5206\u5225\u70ba400 mg\uff081\u4f8b\uff09\u3001600 mg\uff084\u4f8b\uff09\u3001800 mg\uff083\u4f8b\uff09\u548c 1,000 mg\uff082\u4f8b\uff09\u3002  <\/p>\n<p>\u7642\u6548\u6578\u64da\uff1a<\/p>\n<p>A \u7d4431\u4f8b\u53ef\u8a55\u4f30\u60a3\u8005\u4e2d\uff0c\u67093\u4f8b\uff089.7%\uff09\u9054\u5230\u4e86\u5b8c\u5168\u7de9\u89e3\uff08CR\uff09\uff0c7\u4f8b\uff0822.6%\uff09\u9054\u5230\u5f88\u597d\u7684\u90e8\u5206\u7de9\u89e3 (VGPR)\uff0c9\u4f8b\uff0829.0%\uff09\u9054\u5230\u90e8\u5206\u7de9\u89e3 (PR)\u3002\u7e3d\u53cd\u61c9\u7387\uff08ORR\uff09\u70ba61.3%\uff0819\u4f8b\uff09\uff0c10\u4f8b\uff0832.3%\uff09\u9054\u5230\u2265 VGPR\u3002   B\u7d444\u4f8b\u53ef\u8a55\u4f30\u60a3\u8005\u4e2d\uff0c\u67092\u4f8b\uff0850%\uff09\u9054\u5230CR\uff0c2\u4f8b\uff0850%\uff09\u9054\u5230\u2265 VGPR\u3002   C\u7d447\u4f8b\u63a5\u53d7\u8a55\u4f30\u7684\u60a3\u8005\u4e2d\uff0c1\u4f8b\uff0814.3%\uff09\u9054\u5230CR\uff0c4\u4f8b\uff0857.1%\uff09\u9054\u5230 VGPR\uff0c1\u4f8b\uff0814.3%\uff09\u9054\u5230PR\uff0c5\u4f8b\uff0871.4%\uff09\u9054\u5230\u2265 VGPR\uff0cORR \u70ba 85.7%\uff086\u4f8b\uff09\uff1b2\u4f8b\u7372\u5f97\u5fc3\u81df\u53cd\u61c9\u3002  <\/p>\n<p>\u5b89\u5168\u6027\u6578\u64da\uff1a\u572849\u4f8b\u88ab\u7d0d\u5165\u5b89\u5168\u6027\u8a55\u4f30\u7684\u60a3\u8005\u4e2d\uff0c\u670934\u4f8b\uff0869.4%\uff09\u5831\u544a\u4e86\u4efb\u4f55\u7d1a\u5225\u7684APG-2575\uff08Lisaftoclax\uff09\u6cbb\u7642\u76f8\u95dc\u4e0d\u826f\u53cd\u61c9\uff08TRAEs\uff1b\u767c\u751f\u7387\u22655%\uff09\uff0c\u5305\u62ec\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\u75c7\uff0820.4%\uff09\u3001\u8840\u5c0f\u677f\u6e1b\u5c11\uff086.1%\uff09\u3001\u767d\u7d30\u80de\u6e1b\u5c11\uff0810.2%\uff09\u3001\u5641\u5fc3\uff0816.3%\uff09\u3001\u8179\u8139(10.2%\uff09\u3001\u8179\u7009\uff0812.2%\uff09\u548c\u4fbf\u79d8\uff088.2%\uff09\u3002\u5171\u670911\u4f8b\u60a3\u8005\u51fa\u73fe\u4e86\u22653\u7d1a\u7684TRAEs\uff0c\u5305\u62ec\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\uff0814.3%\uff09\u548c\u767c\u71b1\u6027\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\uff082%\uff09\uff0c3\u4f8b\u60a3\u8005\u51fa\u73fe\u4e86\u8207APG-2575\uff08Lisaftoclax\uff09\u76f8\u95dc\u7684\u56b4\u91cdAEs\uff0c\u5206\u5225\u70ba\u767c\u71b1\u6027\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\u3001\u6025\u6027\u814e\u640d\u50b7\u548c\u8179\u7009\u4f34\u96fb\u89e3\u8cea\u5931\u8861\uff08\u54041\u4f8b\uff09\u3002\u5728B\u7d44\u4e2d\uff0c1\u4f8b\u60a3\u8005\u51fa\u73fe\u4e86\u5291\u91cf\u9650\u5236\u6027\u6bd2\u6027\uff08QT\u9593\u671f\u5ef6\u9577\uff09\u3002\u85e5\u4ee3\u52d5\u529b\u5b78\u5206\u6790\u8868\u660e\uff0c\u57283\u500b\u6cbb\u7642\u7d44\u4e2d\uff0c\u6240\u6709\u60a3\u8005\u5728\u63a5\u53d7\u6240\u6307\u5b9a\u5291\u91cf\u7684APG-2575\uff08Lisaftoclax\uff09\u806f\u5408\u5176\u5b83\u6cbb\u7642\u85e5\u7269\u6cbb\u7642\u6642\u5747\u672a\u767c\u751f\u85e5\u7269\u76f8\u4e92\u4f5c\u7528\uff08DDI\uff09\u3002<\/p>\n<p>\u7d50\u8ad6\uff1a\u7814\u7a76\u7d50\u679c\u8868\u660e\uff0cAPG-2575\uff08Lisaftoclax\uff09\u806f\u5408Pd\u6216DRd\u65b9\u6848\u53ef\u63d0\u9ad8R\/R MM\u6216AL\u6fb1\u7c89\u6a23\u8b8a\u6027\u60a3\u8005\u7684\u7de9\u89e3\u6df1\u5ea6\u3002\u9019\u4e9b\u806f\u5408\u7642\u6cd5\u986f\u793a\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\uff0c\u5c24\u5176\u662f\u8840\u6db2\u5b78\u4e0d\u826f\u53cd\u61c9\u65b9\u9762\uff0c\u4e14\u7121\u85e5\u7269\u76f8\u4e92\u4f5c\u7528\u3002<\/p>\n<p>\u58c1\u5831\u5c55\u793a\uff1a<\/p>\n<p>Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given With Accelerated Ramp-up and Then Combined With Acalabrutinib or Rituximab in Patients (pts) With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL), Including Those With Prior Exposure to Venetoclax<br \/>Lisaftoclax\uff08APG-2575\uff09\u5728\u5feb\u901f\u5291\u91cf\u905e\u589e\u7d66\u85e5\u5f8c\u8207\u963f\u53ef\u66ff\u5c3c\u6216\u5229\u59a5\u6614\u55ae\u6297\u806f\u5408\u6cbb\u7642\u5728\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u4e2d\u7684\u5b89\u5168\u6027\u548c\u6297\u816b\u7624\u6d3b\u6027\uff0c\u5305\u62ec\u65e2\u5f80\u63a5\u53d7\u7dad\u5948\u514b\u62c9\u6cbb\u7642\u7684\u60a3\u8005\u00a0<\/p>\n<p>\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a<\/p>\n<p>\u6458\u8981\u7de8\u865f\uff1a4614<\/p>\n<p>\u5206\u6703\u5834\uff1a642. \u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff1a\u81e8\u5e8a\u53ca\u6d41\u884c\u75c5\u5b78\u7814\u7a76\uff1a\u58c1\u5831\u5c55\u793aIII<\/p>\n<p>\u5831\u544a\u6642\u9593\uff1a<\/p>\n<p>2024\u5e7412\u67089\u65e5\uff0c\u661f\u671f\u4e00\uff0c\u4e0b\u534818:00 \u2013 20:00\uff08\u7f8e\u570b\u897f\u90e8\u6642\u9593\uff09<br \/>2024\u5e7412\u670810\u65e5\uff0c\u661f\u671f\u4e8c\uff0c\u4e0a\u534810:00 \u2013 12:00\uff08\u5317\u4eac\u6642\u9593\uff09<\/p>\n<p>\u7b2c\u4e00\u4f5c\u8005\uff1a\u00a0\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff08Dana-Farber Cancer Institute\uff09Matthew S. Davids\u535a\u58eb<\/p>\n<p>\u6838\u5fc3\u8981\u9ede\uff1a<\/p>\n<p>\u7814\u7a76\u80cc\u666f\uff1a\u7dad\u5948\u514b\u62c9\uff08ven\uff09\u5c0dBcl-2\u7684\u6291\u5236\u662fCLL\u6cbb\u7642\u7684\u91cd\u5927\u9032\u5c55\uff0c\u4f46\u70ba\u6e1b\u8f15\u816b\u7624\u6eb6\u89e3\u7d9c\u5408\u5f81\u548c\u85e5\u7269\u76f8\u4e92\u4f5c\u7528\uff08DDI\uff09\u98a8\u96aa\u800c\u9032\u884c\u76845\u5468\u5291\u91cf\u905e\u589e\u7d66\u85e5\u7684\u6cbb\u7642\u65b9\u5f0f\u4e9f\u5f85\u512a\u5316\u3002APG-2575\uff08Lisaftoclax\uff09\u662f\u4e00\u7a2e\u5728\u7814\u7684\u53e3\u670dBcl-2\u6291\u5236\u5291\uff0c\u5176\u534a\u8870\u671f\u77ed\uff0c\u53ef\u4ee5\u505a\u5230\u6bcf\u65e5\u5291\u91cf\u905e\u589e\u7d66\u85e5\u3002<\/p>\n<p>\u7814\u7a76\u4ecb\u7d39\uff1a\u672c\u6b21\u516c\u4f48\u4e86APG-2575\uff08Lisaftoclax\uff09\u55ae\u85e5\u6216\u806f\u5408\u963f\u53ef\u66ff\u5c3c\u6216\u5229\u59a5\u6614\u55ae\u6297\u6cbb\u7642\u521d\u6cbb\u00a0(TN\uff09\u3001\u5fa9\u767c\/\u96e3\u6cbb\u6027\uff08R\/R\uff09\u6216\u65e2\u5f80\u63a5\u53d7\u904e\u7dad\u5948\u514b\u62c9\uff08ven-treated\uff09\u6cbb\u7642\u7684CLL\/SLL\u7684\u6700\u65b0\u81e8\u5e8a\u6578\u64da\u3002<\/p>\n<p>\u5165\u7d44\u60a3\u8005\u548c\u7814\u7a76\u65b9\u6cd5\uff1a<\/p>\n<p>\u5f9e2020\u5e743\u670820\u65e5\u81f32024\u5e746\u670827\u65e5\uff0c\u5171\u5165\u7d44176\u4f8b\u60a3\u8005\uff1a\u55ae\u85e5\u7d4446\u4f8b\uff1b\u806f\u5408\u5229\u59a5\u6614\u55ae\u6297\u7d4439\u4f8b\uff1b\u806f\u5408\u963f\u53ef\u66ff\u5c3c\u7d4491\u4f8b\u3002\u5176\u4e2dR\/R\u536087.5%\uff08154\/176\uff09, TN\u536012.5%\uff0822\/176\uff09\uff1b\u4e2d\u4f4d\uff08\u7bc4\u570d\uff09\u5e74\u9f6163\uff0834-80\uff09\u6b72\uff1b67%\u70ba\u7537\u6027\uff1b25.6% \u4f34\u6709del\uff0817p\uff09\u548c\/\u6216TP53\u7a81\u8b8a\uff1b70.6% \u4f34\u6709\u00a0IGHV\u672a\u7a81\u8b8a\u3002   APG-2575\uff08Lisaftoclax\uff09\u7684\u4e2d\u4f4d\uff08\u7bc4\u570d\uff09\u6301\u7e8c\u6cbb\u7642\u6642\u9593\u5206\u5225\u70ba16.5\uff081-54\uff1b\u55ae\u85e5\u7d44\uff09\u500b\u6708\uff0c24\uff083-39\uff1b\u806f\u5408\u5229\u59a5\u6614\u55ae\u6297\u7d44\uff09\u500b\u6708\u548c27\uff081-43\uff1b\u806f\u5408\u963f\u53ef\u66ff\u5c3c\u7d44\uff09\u500b\u6708\u3002\u5728R\/R\u60a3\u8005\u4e2d\uff0c\u5148\u524d\u7684\u4e2d\u4f4d\uff08\u7bc4\u570d\uff09\u6cbb\u7642\u7dda\u6578\u70ba2\uff081-15\uff09\uff0c14\u4f8b\uff089%\uff09\u60a3\u8005\u66fe\u63a5\u53d7\u904e\u7dad\u5948\u514b\u62c9\u6cbb\u7642\u3002\u65e2\u5f80\u63a5\u53d7\u904e\u7dad\u5948\u514b\u62c9\u6cbb\u7642\u7684\u60a3\u8005\u4e2d\u4f4d\uff08\u7bc4\u570d\uff09\u5e74\u9f61\u70ba65\u6b72\uff0851-78\u6b72\uff09\uff0c79%\u70ba\u7537\u6027\u3002   \u5728\u53ef\u8a55\u4f30\u7684\u60a3\u8005\u4e2d\uff0c50%\u7684\u60a3\u8005\u6709del\uff0817p\uff09\uff0c36%\u7684\u60a3\u8005\u6709TP53\u7a81\u8b8a\uff0c64%\u7684\u60a3\u8005\u6709del\uff0811q\uff09\uff0c38%\u7684\u60a3\u8005\u6709\u8907\u96dc\u7684\u6838\u578b\uff08\u22653\u7a2e\u7570\u5e38\uff09\uff0c92%\u7684\u60a3\u8005\u6709\u672a\u7a81\u8b8a\u7684IGHV\uff1b57%\u7684\u60a3\u8005\u65e2\u5f80\u672a\u63a5\u53d7\u904eBTK\u6291\u5236\u5291\u6cbb\u7642\uff1b\u65e2\u5f80\u6cbb\u7642\u7684\u4e2d\u4f4d\u6578\uff08\u7bc4\u570d\uff09\u7dda\u6578\u70ba3\uff081-6\uff09\u3002   \u60a3\u8005\u6bcf\u5929\u55ae\u7368\u53e3\u670dAPG-2575\uff08Lisaftoclax\uff09\u6216\u8207\u963f\u53ef\u66ff\u5c3c\uff08\u6301\u7e8c\u6cbb\u7642\uff09\/\u5229\u59a5\u6614\u55ae\u6297\uff086\u500b\u7642\u7a0b\uff09\u806f\u5408\u6cbb\u7642\uff0c\u6bcf28\u5929\u70ba\u4e00\u7642\u7a0b\u3002APG-2575\uff08Lisaftoclax\uff09\u63a1\u75284-6\u5929\u6bcf\u5929\u68af\u5ea6\u905e\u589e\u7d66\u85e5\u7684\u65b9\u5f0f\uff0c\u5f9e20mg\u958b\u59cb\uff0c4-6\u5929\u5f8c\u53ef\u9054\u5230\u6700\u7d42\u7684\u76ee\u6a19\u5291\u91cf\uff08400\u3001600\u6216800 mg\uff09\u3002\u806f\u5408\u6cbb\u7642\u7d44\u4e2d\u7684\u60a3\u8005\u5f9e\u7b2c1\u9031\u671f\u7684\u7b2c8\u5929\uff08C1D8\uff09\u958b\u59cb\u52a0\u5165\u963f\u53ef\u66ff\u5c3c\u6216\u5229\u59a5\u6614\u55ae\u6297\u6cbb\u7642\uff0c\u76f4\u81f3\u9032\u5c55\u6216\u7b2c24\u500b\u9031\u671f\u5be6\u73fe\u5b8c\u5168\u7de9\u89e3\uff08CR\uff09\u6216\u8005\u89c0\u5bdf\u5230\u4e0d\u53ef\u8010\u53d7\u7684\u6bd2\u6027\u3002  <\/p>\n<p>\u7642\u6548\u6578\u64da\uff1a<\/p>\n<p>\u572887\u4f8b\u63a5\u53d7APG-2575\uff08Lisaftoclax\uff09\u806f\u5408\u963f\u53ef\u66ff\u5c3c\u6cbb\u7642\u7684\u60a3\u8005\u4e2d\uff0cORR\u70ba96.6%\uff0c\u4e2d\u4f4d\u7de9\u89e3\u6301\u7e8c\u6642\u9593\uff08DOR; 95% CI, 23-NR\uff09\u548c\u4e2d\u4f4d\u7121\u9032\u5c55\u751f\u5b58\u671f\uff08PFS; 95% CI, 34-NR\uff09\u5747\u672a\u9054\u5230\u300212\u500b\u6708\u548c18\u500b\u6708\u7684PFS\u7387\u5206\u5225\u70ba89%\u548c86%\u3002<\/p>\n<p>\u806f\u5408\u963f\u53ef\u66ff\u5c3c\u6cbb\u7642\u7d44\u4e2d\uff0c\u670914\u4f8b\u66fe\u63a5\u53d7\u904e\u7dad\u5948\u514b\u62c9\u6cbb\u7642:<\/p>\n<p>\u5176\u4e2d9\u4f8b\u5728\u65e2\u5f80\u7dad\u5948\u514b\u62c9\u6cbb\u7642\u4e2d\u9032\u5c55\uff0c3\u4f8b\u5728\u5b8c\u6210\u7dad\u5948\u514b\u62c9\u6cbb\u7642\u5f8c\u5fa9\u767c\uff0c2\u4f8b\u56e0\u7dad\u5948\u514b\u62c9\u4e0d\u8010\u53d7\u800c\u505c\u85e5\u3002\u4e2d\u4f4d\uff08\u7bc4\u570d\uff09\u6cbb\u7642\u6301\u7e8c\u6642\u9593\u70ba16\uff083-25\uff09\u500b\u6708\u3002\u5b89\u5168\u6027\u8207\u5176\u4ed6\u7814\u7a76\u968a\u5217\u76f8\u4f3c\u3002   \u5728\u65e2\u5f80\u63a5\u53d7\u904e\u7dad\u5948\u514b\u62c9\u6cbb\u7642\u7684\u60a3\u8005\u4e2d\uff0cORR\u70ba85.7%\uff0812\/14\uff09\uff1b   \u5728\u65e2\u5f80\u63a5\u53d7\u904e\u7dad\u5948\u514b\u62c9\u4f46\u672a\u63a5\u53d7\u904eBTK\u6291\u5236\u5291\u6cbb\u7642\u7684\u60a3\u8005\u4e2d\uff0cORR\u70ba100%\uff088\/8\uff09\uff1b   \u5728\u65e2\u5f80\u63a5\u53d7\u904e\u7dad\u5948\u514b\u62c9\u548cBTK\u6291\u5236\u5291\u6cbb\u7642\u7684\u60a3\u8005\u4e2d\uff0cORR\u70ba66.7%\uff084\/6\uff09\uff1b   \u4e2d\u4f4dDOR\u548cPFS\u672a\u9054\u5230\u300212\u500b\u6708\u548c18\u500b\u6708\u7684PFS\u7387\u5206\u5225\u70ba84%\u548c73%\u3002  <\/p>\n<p>\u5b89\u5168\u6027\u6578\u64da\uff1a<\/p>\n<p>\u5404\u968a\u5217TEAEs\u7684\u767c\u751f\u7387\u548c\u56b4\u91cd\u7a0b\u5ea6\u76f8\u4f3c\u3002   \u6240\u6709\u968a\u5217\u4e2d\u5e38\u898b\u7684\uff08&gt;10%\uff09\u4efb\u610f\u7d1a\u5225TEAEs \u70ba\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\uff0859\u4f8b[33.5%]\uff09\u3001\u8179\u7009\uff0838\u4f8b[21.6%]\uff09\u3001\u8ca7\u8840\uff0827\u4f8b[15.3%]\uff09\u548c\u8840\u5c0f\u677f\u6e1b\u5c11\uff0826\u4f8b[14.8%]\uff09\u3002 \u22653\u7d1aTEAEs\u5728\u55ae\u85e5\u7d44\u3001\u806f\u5408\u5229\u59a5\u6614\u55ae\u6297\u7d44\u548c\u806f\u5408\u963f\u53ef\u66ff\u5c3c\u7d44\u4e2d\u5206\u5225\u70ba\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c1115\u4f8b\uff0832.6%\uff09\u300110\u4f8b\uff0825.6%\uff09\u548c22\u4f8b\uff0824%\uff09\uff0c\u8ca7\u884010\u4f8b\uff0821.7%\uff09\u30015\u4f8b\uff0812.8%\uff09\u548c12\u4f8b\uff0813.2%\uff09\u3002\u7d9c\u5408E\u2011R\u5206\u6790\u8868\u660e\uff0cAPG-2575\uff08Lisaftoclax\uff09\u4f5c\u70ba\u55ae\u85e5\u6cbb\u7642\u6216\u806f\u5408\u963f\u53ef\u66ff\u5c3c\u6216\u5229\u59a5\u6614\u55ae\u6297\u6cbb\u7642\u6642\u6709\u76f8\u4f3c\u7684\u5168\u8eab\u66b4\u9732\uff1bAPG-2575\uff08Lisaftoclax\uff09\u8207\u963f\u53ef\u66ff\u5c3c\u6216\u5229\u59a5\u6614\u55ae\u6297\u806f\u5408\u4f7f\u7528\u6642\u7121DDI\u3002   \u6c92\u6709\u8207APG-2575\uff08Lisaftoclax\uff09\u76f8\u95dc\u7684TRAEs\u5c0e\u81f4\u505c\u85e5\u300244\u4f8b\uff0895.7%\uff09\u63a5\u53d7\u55ae\u85e5\u6cbb\u7642\u7684\u60a3\u8005\u505c\u6b62\u4e86\u6cbb\u7642\u3002\u4e3b\u8981\u505c\u85e5\u539f\u56e0\u662f\u75be\u75c5\u9032\u5c55\uff0841 \u4f8b[23.3%]\uff09\u548c AE\uff08 13 \u4f8b[7.4%] \uff09\uff1b9\u4f8b\uff085.1%\uff09\u60a3\u8005\u64a4\u56de\u77e5\u60c5\u540c\u610f\uff1b7\u4f8b\uff084%\uff09\u5728\u7b2c24\u500b\u9031\u671f\u53ca\u4ee5\u5f8c\u7372\u5f97\u5b8c\u5168\u7de9\u89e3\u6216MRD\u9670\u6027\uff1b\u6b7b\u4ea15\u4f8b\uff082.8%\uff09\uff1b18\u4f8b\uff0810.2%\uff09\u56e0\u5176\u4ed6\u539f\u56e0\u505c\u85e5\u30025\u4f8b\uff082.8%\uff09\u63a5\u53d7APG-2575\uff08Lisaftoclax\uff09\u6cbb\u7642\u7684\u60a3\u8005\u89c0\u5bdf\u5230\u81e8\u5e8a\uff08n=2\uff09\u548c\u5be6\u9a57\u5ba4\uff08n=3\uff09TLS\uff08\u6839\u64daHoward\/Cairo-Bishop\u6a19\u6e96\uff09\uff0c\u9019\u4e9b\u60a3\u8005\u8fc5\u901f\u6062\u5fa9\u4e26\u7e7c\u7e8c\u5b89\u5168\u63a5\u53d7APG-2575\uff08Lisaftoclax\uff09\u6cbb\u7642\u3002  <\/p>\n<p>\u7d50\u8ad6\uff1a\u6b64\u6b21\u7814\u7a76\u6578\u64da\u8868\u660e\uff0cAPG-2575\uff08Lisaftoclax\uff09\u806f\u5408\u963f\u53ef\u66ff\u5c3c\u5c0d\u65e2\u5f80\u63a5\u53d7\u904e\u7dad\u5948\u514b\u62c9\u6cbb\u7642\u7684\u60a3\u8005\u6709\u6548\uff0c\u5305\u62ec\u5728\u7dad\u5948\u514b\u62c9\u6cbb\u7642\u4e2d\u9032\u5c55\u7684\u60a3\u8005\u3002\u9019\u9805\u96a8\u8a2a\u6642\u9593\u8f03\u9577\u7684\u66f4\u65b0\u5206\u6790\u986f\u793a\uff0c\u5728\u63a5\u53d7APG-2575\uff08Lisaftoclax\uff09\u55ae\u85e5\u6cbb\u7642\/\u806f\u5408\u6cbb\u7642\u7684\u521d\u6cbb\u6216R\/R CLL\/SLL\u60a3\u8005\u4e2d\u672a\u89c0\u5bdf\u5230DDI\u6216\u65b0\u7684\u5b89\u5168\u6027\u554f\u984c\u3002\u6211\u5011\u6703\u7e7c\u7e8c\u7a4d\u7d2f\u65e2\u5f80\u63a5\u53d7\u904e\u7dad\u5948\u514b\u62c9\u6cbb\u7642\u7684\u60a3\u8005\u6578\u64da\u4f86\u9032\u4e00\u6b65\u8b49\u5be6\u9019\u4e00\u9f13\u821e\u4eba\u5fc3\u7684\u7d50\u679c\u3002APG-2575\uff08Lisaftoclax\uff09\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\u76ee\u524d\u6b63\u5728\u5165\u7d44\u4e2d\u3002<\/p>\n<p>Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)\u00a0 <br \/>\u65b0\u578bBcl-2\u6291\u5236\u5291Lisaftoclax\uff08APG-2575\uff09\u806f\u5408\u963f\u624e\u80de\u7518\u6cbb\u7642\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\uff08MDS\uff09<\/p>\n<p>\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a<\/p>\n<p>\u6458\u8981\u7de8\u865f\uff1a3202<\/p>\n<p>\u5206\u6703\u5834\uff1a637. \u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\uff1a\u81e8\u5e8a\u53ca\u6d41\u884c\u75c5\u5b78\u7814\u7a76\uff1a\u58c1\u5831\u5c55\u793aII<\/p>\n<p>\u5831\u544a\u6642\u9593\uff1a<\/p>\n<p>2024\u5e7412\u67088\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0b\u534818:00 \u2013 20:00\uff08\u7f8e\u570b\u897f\u90e8\u6642\u9593\uff09\/<br \/>2024\u5e7412\u67089\u65e5\uff0c\u661f\u671f\u4e00\uff0c\u4e0a\u534810:00 \u2013 12:00\uff08\u5317\u4eac\u6642\u9593\uff09<\/p>\n<p>\u7b2c\u4e00\u4f5c\u8005\uff1a\u738b\u83ef\u92d2\u6559\u6388\uff0c\u6d59\u6c5f\u5927\u5b78\u91ab\u5b78\u9662\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662<\/p>\n<p>\u6838\u5fc3\u8981\u9ede\uff1a<\/p>\n<p>\u7814\u7a76\u80cc\u666f\uff1a\u53bb\u7532\u57fa\u5316\u85e5\u7269\uff08HMA\uff09\u4ecd\u7136\u662f\u9ad8\u5371MDS\u7684\u6a19\u6e96\u6cbb\u7642\uff0c\u4f46\u81e8\u5e8a\u7642\u6548\u6b20\u4f73\u3002\u800cHMA\u6cbb\u7642\u5931\u6557\/\u8010\u85e5\u7684MDS\u60a3\u8005\uff0c\u9810\u5f8c\u5f88\u5dee\uff0c\u9019\u4e9b\u9ad8\u5371MDS\u60a3\u8005\u4e9f\u9700\u65b0\u7684\u6cbb\u7642\u65b9\u6848\u3002<\/p>\n<p>\u7814\u7a76\u4ecb\u7d39\uff1a\u81e8\u5e8a\u524d\u6578\u64da\u986f\u793a\uff0c\u65b0\u578b\u7684Bcl-2\u6291\u5236\u5291APG-2575\uff08Lisaftoclax\uff09\u8207HMA\u806f\u5408\u53ef\u5354\u540c\u8a98\u5c0eAML\u548cMDS\u816b\u7624\u7d30\u80de\u7684\u51cb\u4ea1\u3002\u6b64\u6b21\u6703\u8b70\u5831\u544a\u7684\u662f\u4e00\u9805Ib\/II\u671f\u81e8\u5e8a\u8a66\u9a57\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u96a8\u8a2a\u6578\u64da\uff0c\u91cd\u9ede\u8a55\u4f30APG-2575\uff08Lisaftoclax\uff09\u806f\u5408\u963f\u624e\u80de\u7518\u6cbb\u7642\u6210\u4ebaMDS\u60a3\u8005\u7684\u7642\u6548\u3002<\/p>\n<p>\u5165\u7d44\u60a3\u8005\u548c\u7814\u7a76\u65b9\u6cd5\uff1a<\/p>\n<p>\u8a72\u7814\u7a76\u7d0d\u5165\u9ad8\u5371MDS\u60a3\u8005\uff08IPSS-R\u8a55\u5206&gt; 3.5\uff1b\u9aa8\u9ad3\u539f\u59cb\u7d30\u80de&gt;5%\uff09\uff0c\u5305\u62ec\u521d\u6cbb\uff08TN\uff09\u548cR\/R MDS\u60a3\u8005\u3002APG-2575\uff08Lisaftoclax\uff09\u4f7f\u7528\u6307\u5b9a\u5291\u91cf\uff08400mg, 600mg\u6216800mg\uff09\uff0c\u6bcf\u5929\u4e00\u6b21\uff0c\u7b2c1\u5929\u81f3\u7b2c14\u5929\u4f7f\u7528\uff1b\u5728\u7b2c1\u5929\u81f3\u7b2c7\u5929\u806f\u5408\u4f7f\u7528\u963f\u624e\u80de\u7518(75mg \/m2\/\u5929)\uff0c\u6bcf28\u5929\u70ba\u4e00\u500b\u6cbb\u7642\u9031\u671f\u3002\u5728\u7b2c\u4e00\u500b\u6cbb\u7642\u9031\u671f\u4e2d\uff0cAPG-2575\uff08Lisaftoclax\uff09\u63a1\u7528\u6bcf\u65e5\u5291\u91cf\u905e\u589e\u65b9\u6848\u4ee5\u9810\u9632\u816b\u7624\u6eb6\u89e3\u7d9c\u5408\u5f81(TLS)\u3002\u8a72\u7814\u7a76\u7684\u4e3b\u8981\u76ee\u7684\u662f\u8a55\u4f30\u6b64\u806f\u5408\u7642\u6cd5\u6cbb\u7642MDS\u60a3\u8005\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\uff0c\u4e26\u78ba\u5b9aAPG-2575\uff08Lisaftoclax\uff09\u7684\u63a8\u85a6III\u671f\u5291\u91cf\u3002\u6839\u64da2006\u5e74\u570b\u969b\u5de5\u4f5c\u7d44\uff08IWG\uff09\u6a19\u6e96\u8a55\u4f30\u5b8c\u5168\u7de9\u89e3\uff08CR\uff09\u548c\u9aa8\u9ad3\u5b8c\u5168\u7de9\u89e3\u7387\uff08mCR)\u3002   \u622a\u81f32024\u5e747\u67081\u65e5\uff0c\u5171\u670949\u4f8b\u60a3\u8005\u5165\u7d44\uff1a8\u4f8b\u70baR\/R MDS\uff08APG-2575 [Lisaftoclax] 600 mg [n = 5]\u548c800 mg [n = 3]\uff09\uff0c41\u4f8b\u70baTN MDS\uff08APG-2575 [Lisaftoclax] 400 mg [n = 16]\u3001600 mg [n = 23]\u548c800 mg [n = 2]\uff09\u3002\u4e2d\u4f4d\uff08\u7bc4\u570d\uff09\u5e74\u9f61\u70ba66\uff0822-83\uff09\u6b72\uff0c55.1%\u7684\u60a3\u8005\u70ba\u7537\u6027\u3002IPSS-R\u98a8\u96aa\u5206\u7d1a\u70ba\u4e2d\u5371\uff0812\/49[24.5%]\uff09\u3001\u9ad8\u5371\uff0824\/49[49.0%]\uff09\u548c\u6975\u9ad8\u5371\uff0813\/49[26.5%]\uff09\u300239\u4f8b\u6709\u57fa\u56e0\u7a81\u8b8a\u8b5c\u6578\u64da\u7684\u60a3\u8005\u4e2d\uff0c9\u4f8b\uff0823.1%\uff09\u6709TP53\u7a81\u8b8a\uff1b11\u4f8b\uff0828.2%\uff09\u6709TET2\u7a81\u8b8a\uff1b10\u4f8b\uff0825.6%\uff09\u6709ASXL1\u7a81\u8b8a\uff1b10\u4f8b\uff0825.6%\uff09\u6709RUNX1\u7a81\u8b8a\u3002\u57fa\u7dda\u6642\uff0c70.8%\u7684\u60a3\u8005\u5831\u544a\u4e86\u22653\u7d1a\u8ca7\u8840\uff1b54.2%\u5831\u544a\u4e86\u22653\u7d1a\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\uff1b45.8%\u5831\u544a\u4e86\u22653\u7d1a\u8840\u5c0f\u677f\u6e1b\u5c11\u75c7\u3002  <\/p>\n<p>\u7642\u6548\u6578\u64da\uff1a4\u4f8b\uff088.2%\uff09\u60a3\u8005\u66fe\u56e0\u4e0d\u826f\u4e8b\u4ef6\u5f15\u8d77APG-2575\uff08Lisaftoclax\uff09\u6e1b\u91cf\u300260\u5929\u6b7b\u4ea1\u7387\u548cTLS\u767c\u751f\u7387\u5747\u70ba0\u3002\u57288\u4f8bR\/R MDS\u60a3\u8005\u4e2d\uff0c\u4e2d\u4f4d\u6cbb\u7642\u6642\u9593\uff08DOT\uff09\u70ba3.2\uff081.2-9.4\uff09\u500b\u6708\u3002\u7e3d\u53cd\u61c9\u7387\uff08ORR = CR[12.5%] +mCR[62.5%]\uff09\u70ba75.0%\uff0895% CI, 34.9-96.8\uff09\u3002\u572840\u4f8b\u53ef\u8a55\u4f30\u7642\u6548\u7684TN MDS\u60a3\u8005\u4e2d\uff0c\u4e2d\u4f4dDOT\u70ba4.5\uff080.5-12.1\uff09\u500b\u6708\uff1b\u6839\u64daIWG 2006\u6a19\u6e96\uff0cORR\u7387\u70ba77.5%\uff0895% CI, 61.5-89.2\uff09\uff0cCR\u7387\u70ba25.0%\u3002\u6b64\u5916\uff0c23\u4f8b\u63a5\u53d7APG-2575\uff08Lisaftoclax\uff09600 mg\u806f\u5408\u963f\u624e\u80de\u7518\u6cbb\u7642\u7684TN MDS\u60a3\u8005\u4e2d\uff0cORR\u548cCR\u7387\u5206\u5225\u70ba73.9%\u548c30.4%\uff1b\u7531\u65bc\u9019\u4e9b\u60a3\u8005\u7684\u4e2d\u4f4d\u6cbb\u7642\u6642\u9593\u76f8\u5c0d\u8f03\u9577\uff086.01\u500b\u6708\uff09\uff0c\u6211\u5011\u6839\u64daIWG 2023\u6a19\u6e96\u9032\u884c\u4e86\u9032\u4e00\u6b65\u5206\u6790\uff0c\u5fa9\u5408CR\u7387\uff08CR2023 = CR [52.2%] + CRL[17.4%]\uff09\u70ba69.6%\uff0c\u4e2d\u4f4d\u9054\u5230CR\u6642\u9593\uff08\u7bc4\u570d\uff09\u70ba2.84\uff081.1-8.7\uff09\u500b\u6708\u3002\u4e2d\u4f4d\u7121\u9032\u5c55\u751f\u5b58\u671f\u548c\u4e2d\u4f4d\u7e3d\u751f\u5b58\u671f\u5747\u672a\u9054\u5230\u3002<\/p>\n<p>\u5b89\u5168\u6027\u6578\u64da\uff1a<\/p>\n<p>\u6240\u6709\u63a5\u53d7APG-2575\uff08Lisaftoclax\uff09\u806f\u5408\u963f\u624e\u80de\u7518\u6cbb\u7642\u7684\u60a3\u8005\u5747\u5831\u544a\u4e86\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u4e0d\u826f\u4e8b\u4ef6(TEAEs)\uff0c\u5176\u4e2d93.8%\u70ba\u22653\u7d1a\u4e0d\u826f\u4e8b\u4ef6\uff0c35.4%\u70ba\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6\u3002\u5e38\u898b\u7684\u22653\u7d1a\u975e\u8840\u6db2\u5b78TEAEs\uff08\u767c\u751f\u7387\u226510%\uff09\u5305\u62ec\u80ba\u708e\uff0824.4%\uff09\u548c\u4f4e\u9240\u8840\u75c7\uff0810.2%\uff09\u3002\u5e38\u898b\u7684\u22653\u7d1a\u8840\u6db2\u5b78TEAEs\u5305\u62ec\u767d\u7d30\u80de\u8a08\u6578\u6e1b\u5c11\uff0875.5%\uff09\u3001\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\uff0869.4%\uff09\u3001\u8840\u5c0f\u677f\u6e1b\u5c11\uff0865.3%\uff09\u3001\u8ca7\u8840\uff0824.5%\uff09\u548c\u767c\u71b1\u6027\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\uff0818.4%\uff09\u3002   46.9%\u7684\u60a3\u8005\u5831\u544a\u22653\u7d1a\u611f\u67d3\uff0c\u5176\u4e2d26.5%\u8207\u6cbb\u7642\u76f8\u95dc\u300211\u4f8b\uff0822.4%\uff09\u60a3\u8005\u767c\u751f\u4e86\u56e0\u4e0d\u826f\u4e8b\u4ef6\u5c0e\u81f4\u7684\u9031\u671f\u9593\u6cbb\u7642\u5ef6\u9072\uff0c\u4e2d\u4f4d\u5ef6\u9072\u6642\u9593(\u7bc4\u570d)\u70ba12\uff081-63\uff09\u5929\u3002   \u5171\u670995.9%\u7684\u60a3\u8005\u5831\u544a\u4e86\u8207\u6cbb\u7642\u76f8\u95dc\u7684\u4e0d\u826f\u4e8b\u4ef6\uff08TRAEs\uff09\uff0c\u5176\u4e2d87.8%\u70ba\u22653\u7d1aAEs\uff0c28.6%\u70ba\u56b4\u91cdAEs\u3002\u5e38\u898b\u7684\u22653\u7d1a\u8840\u6db2\u5b78TRAEs\u5305\u62ec\u767d\u7d30\u80de\u8a08\u6578\u6e1b\u5c11\uff0871.4%\uff09\u3001\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\uff0865.3%\uff09\u3001\u8840\u5c0f\u677f\u6e1b\u5c11\uff0865.3%\uff09\u3001\u8ca7\u8840\uff0820.4%\uff09\u548c\u767c\u71b1\u6027\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\uff0812.2%\uff09\u3002  <\/p>\n<p>\u7d50\u8ad6\uff1a\u4ee5\u4e0a\u81e8\u5e8a\u6578\u64da\u8868\u660e\uff0cAPG-2575\uff08Lisaftoclax\uff09\u806f\u5408\u963f\u624e\u80de\u7518\u5728\u9ad8\u5371TN\u6216R\/R MDS\u60a3\u8005\u6cbb\u7642\u4e2d\u5177\u6709\u91cd\u8981\u4f5c\u7528\u3002\u8a72\u806f\u5408\u6cbb\u7642\u5448\u73fe\u826f\u597d\u7684\u6709\u6548\u6027\u548c\u8010\u53d7\u6027\uff0c60\u5929\u6b7b\u4ea1\u7387\u70ba0\uff0c\u9700\u8981APG-2575\uff08Lisaftoclax\uff09\u6e1b\u91cf\u7684\u60a3\u8005\u5c11\uff0c\u611f\u67d3\u7387\u4f4e\uff0c\u652f\u6301\u8a72\u806f\u5408\u6cbb\u7642\u5728\u9ad8\u98a8\u96aaMDS\u60a3\u8005\u7684\u9032\u4e00\u6b65\u81e8\u5e8a\u958b\u767c\u3002<\/p>\n<p>\u95dc\u65bc\u4e9e\u76db\u91ab\u85e5<\/p>\n<p>\u4e9e\u76db\u91ab\u85e5\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u7b49\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u30022019\u5e7410\u670828\u65e5\uff0c\u516c\u53f8\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e3b\u677f\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6855.HK\u3002<\/p>\n<p>\u4e9e\u76db\u91ab\u85e5\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u3001IAP \u6216\u00a0MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\uff1b\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u7b49\uff0c\u70ba\u5168\u7403\u552f\u4e00\u5728\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u9818\u57df\u5747\u6709\u81e8\u5e8a\u958b\u767c\u54c1\u7a2e\u7684\u5275\u65b0\u516c\u53f8\u3002\u76ee\u524d\u516c\u53f8\u5df2\u5728\u4e2d\u570b\u3001\u7f8e\u570b\u3001\u6fb3\u5927\u5229\u4e9e\u53ca\u6b50\u6d32\u958b\u5c5540\u591a\u9805\u81e8\u5e8a\u8a66\u9a57\uff0c\u5176\u4e2d\u5305\u62ec13\u9805\u8a3b\u518a\u81e8\u5e8a\u7814\u7a76\uff08\u5df2\u5b8c\u6210\/\u9032\u884c\u4e2d\/\u64ec\u555f\u52d5\uff09\u3002<\/p>\n<p>\u7528\u65bc\u6cbb\u7642\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u7684\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u66fe\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\u65b0\u85e5\u5be9\u8a55\u4e2d\u5fc3\uff08CDE\uff09\u7d0d\u5165\u512a\u5148\u5be9\u8a55\u548c\u7a81\u7834\u6027\u6cbb\u7642\u54c1\u7a2e\uff0c\u4e26\u5df2\u5728\u4e2d\u570b\u7372\u6279\uff0c\u662f\u516c\u53f8\u7684\u9996\u500b\u4e0a\u5e02\u54c1\u7a2e\u3002\u76ee\u524d\uff0c\u8010\u7acb\u514b\u5df2\u88ab\u6210\u529f\u7d0d\u5165\u300a\u570b\u5bb6\u57fa\u672c\u91ab\u7642\u4fdd\u96aa\u3001\u5de5\u50b7\u4fdd\u96aa\u548c\u751f\u80b2\u4fdd\u96aa\u85e5\u54c1\u76ee\u9304\u300b\u3002\u8a72\u54c1\u7a2e\u9084\u7372\u5f97\u4e86\u7f8e\u570bFDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u3001\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\u4ee5\u53ca\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\u3002<\/p>\n<p>\u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f8\u5171\u67094\u500b\u5728\u7814\u65b0\u85e5\u7372\u5f9716\u9805FDA\u548c1\u9805\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\uff0c2\u9805FDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u4ee5\u53ca2\u9805FDA\u5152\u7ae5\u7f55\u898b\u75c5\u8cc7\u683c\u8a8d\u8b49\u3002\u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u7bc4\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u4f48\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u9ed8\u6c99\u6771\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u9818\u5148\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u4ee5\u53caMD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\uff08MD Anderson Cancer Center\uff09\u3001\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\uff08Mayo Clinic\uff09\u3001\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff08Dana-Farber Cancer Institute\uff09\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\uff08NCI\uff09\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u9054\u6210\u5168\u7403\u5408\u4f5c\u95dc\u4fc2\u3002<\/p>\n<p>\u4e9e\u76db\u91ab\u85e5\u5df2\u69cb\u5efa\u5728\u539f\u5275\u65b0\u85e5\u7814\u767c\u8207\u81e8\u5e8a\u958b\u767c\u9818\u57df\u7d93\u9a57\u8c50\u5bcc\u7684\u570b\u969b\u5316\u4eba\u624d\u5718\u968a\uff0c\u4ee5\u53ca\u6210\u719f\u7684\u5546\u696d\u5316\u751f\u7522\u8207\u5e02\u5834\u71df\u92b7\u5718\u968a\u3002\u4e9e\u76db\u91ab\u85e5\u5c07\u4e0d\u65b7\u63d0\u9ad8\u7814\u767c\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u9032\u516c\u53f8\u7522\u54c1\u7ba1\u7dda\u7684\u81e8\u5e8a\u958b\u767c\u9032\u5ea6\uff0c\u771f\u6b63\u8e10\u884c\u300c\u89e3\u6c7a\u4e2d\u570b\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u300d\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002<\/p>\n<p>\u524d\u77bb\u6027\u8072\u660e<\/p>\n<p>\u672c\u6587\u6240\u4f5c\u51fa\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u8207\u672c\u6587\u4f5c\u51fa\u8a72\u9673\u8ff0\u7576\u65e5\u7684\u4e8b\u4ef6\u6216\u8cc7\u6599\u6709\u95dc\u3002\u9664\u6cd5\u5f8b\u898f\u5b9a\u5916\uff0c\u65bc\u4f5c\u51fa\u524d\u77bb\u6027\u9673\u8ff0\u7576\u65e5\u4e4b\u5f8c\uff0c\u7121\u8ad6\u662f\u5426\u51fa\u73fe\u65b0\u8cc7\u6599\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u6211\u5011\u4e26\u7121\u8cac\u4efb\u66f4\u65b0\u6216\u516c\u958b\u4fee\u6539\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u53ca\u9810\u6599\u4e4b\u5916\u7684\u4e8b\u4ef6\u3002\u8acb\u7d30\u95b1\u672c\u6587\uff0c\u4e26\u7406\u89e3\u6211\u5011\u7684\u5be6\u969b\u672a\u4f86\u696d\u7e3e\u6216\u8868\u73fe\u53ef\u80fd\u8207\u9810\u671f\u6709\u91cd\u5927\u5dee\u7570\u3002\u672c\u6587\u5167\u6240\u6709\u9673\u8ff0\u4e43\u672c\u6587\u7ae0\u520a\u767c\u65e5\u671f\u4f5c\u51fa\uff0c\u53ef\u80fd\u56e0\u672a\u4f86\u767c\u5c55\u800c\u51fa\u73fe\u8b8a\u52d5\u3002<\/p>","protected":false},"excerpt":{"rendered":"<p>\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde2024\u5e7411\u67086\u65e5 \/\u7f8e\u901a\u793e\/ &#8212;\u00a0\u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u4f48\uff0c\u516c\u53f8\u91cd\u9ede\u54c1\u7a2eAPG-2575\uff08Lisaftoclax\uff09\u5171\u67093\u9805\u81e8\u5e8a\u9032\u5c55\u7372\u9078\u7b2c66\u5c46\u7f8e\u570b\u8840\u6db2\u5b78\u6703\uff08American Society of Hematology\uff0cASH\uff09\u5e74\u6703\uff0c\u5176\u4e2d\u4e00\u9805\u7372\u53e3\u982d\u5831\u544a\u3002\u9019\u662f\u8a72\u54c1\u7a2e\u7684\u81e8\u5e8a\u9032\u5c55\u9023\u7e8c\u7b2c3\u5e74\u5165\u9078ASH\u5e74\u6703\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u4eca\u5e74\u516c\u53f8\u56db\u500b\u54c1\u7a2e\uff08\u8010\u7acb\u514b\u3001APG-2575\u3001APG-2449\u3001APG-591 &#8230; <\/p>\n<p class=\"read-more-container\"><a title=\"\u30102024 ASH\u3011 \u4e9e\u76db\u91ab\u85e5Bcl-2\u6291\u5236\u5291APG-2575\u4e09\u9805\u81e8\u5e8a\u7814\u7a76\u5165\u9078\uff0c\u542b1\u9805\u53e3\u982d\u5831\u544a\uff01\" class=\"read-more button\" href=\"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91-%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5bcl-2%e6%8a%91%e5%88%b6%e5%8a%91apg-2575%e4%b8%89%e9%a0%85%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%90%ab1\/22994#more-22994\" aria-label=\"\u66f4\u591a \u30102024 ASH\u3011 \u4e9e\u76db\u91ab\u85e5Bcl-2\u6291\u5236\u5291APG-2575\u4e09\u9805\u81e8\u5e8a\u7814\u7a76\u5165\u9078\uff0c\u542b1\u9805\u53e3\u982d\u5831\u544a\uff01\">\u4e86\u89e3\u8a73\u60c5<\/a><\/p>\n","protected":false},"author":0,"featured_media":22995,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_generate-full-width-content":"","spay_email":"","footnotes":""},"categories":[1],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>\u30102024 ASH\u3011 \u4e9e\u76db\u91ab\u85e5Bcl-2\u6291\u5236\u5291APG-2575\u4e09\u9805\u81e8\u5e8a\u7814\u7a76\u5165\u9078\uff0c\u542b1\u9805\u53e3\u982d\u5831\u544a\uff01 - \u9999\u6e2f\u7279\u8a31\u7d93\u71df<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91-%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5bcl-2%e6%8a%91%e5%88%b6%e5%8a%91apg-2575%e4%b8%89%e9%a0%85%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%90%ab1\/22994\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u30102024 ASH\u3011 \u4e9e\u76db\u91ab\u85e5Bcl-2\u6291\u5236\u5291APG-2575\u4e09\u9805\u81e8\u5e8a\u7814\u7a76\u5165\u9078\uff0c\u542b1\u9805\u53e3\u982d\u5831\u544a\uff01 - \u9999\u6e2f\u7279\u8a31\u7d93\u71df\" \/>\n<meta property=\"og:description\" content=\"\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde2024\u5e7411\u67086\u65e5 \/\u7f8e\u901a\u793e\/ &#8212;\u00a0\u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u4f48\uff0c\u516c\u53f8\u91cd\u9ede\u54c1\u7a2eAPG-2575\uff08Lisaftoclax\uff09\u5171\u67093\u9805\u81e8\u5e8a\u9032\u5c55\u7372\u9078\u7b2c66\u5c46\u7f8e\u570b\u8840\u6db2\u5b78\u6703\uff08American Society of Hematology\uff0cASH\uff09\u5e74\u6703\uff0c\u5176\u4e2d\u4e00\u9805\u7372\u53e3\u982d\u5831\u544a\u3002\u9019\u662f\u8a72\u54c1\u7a2e\u7684\u81e8\u5e8a\u9032\u5c55\u9023\u7e8c\u7b2c3\u5e74\u5165\u9078ASH\u5e74\u6703\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u4eca\u5e74\u516c\u53f8\u56db\u500b\u54c1\u7a2e\uff08\u8010\u7acb\u514b\u3001APG-2575\u3001APG-2449\u3001APG-591 ... \u4e86\u89e3\u8a73\u60c5\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91-%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5bcl-2%e6%8a%91%e5%88%b6%e5%8a%91apg-2575%e4%b8%89%e9%a0%85%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%90%ab1\/22994\" \/>\n<meta property=\"og:site_name\" content=\"\u9999\u6e2f\u7279\u8a31\u7d93\u71df\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-05T23:49:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91-%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5bcl-2%e6%8a%91%e5%88%b6%e5%8a%91apg-2575%e4%b8%89%e9%a0%85%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%90%ab1\/22994#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91-%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5bcl-2%e6%8a%91%e5%88%b6%e5%8a%91apg-2575%e4%b8%89%e9%a0%85%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%90%ab1\/22994\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"\u30102024 ASH\u3011 \u4e9e\u76db\u91ab\u85e5Bcl-2\u6291\u5236\u5291APG-2575\u4e09\u9805\u81e8\u5e8a\u7814\u7a76\u5165\u9078\uff0c\u542b1\u9805\u53e3\u982d\u5831\u544a\uff01\",\"datePublished\":\"2024-11-05T23:49:00+00:00\",\"dateModified\":\"2024-11-05T23:49:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91-%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5bcl-2%e6%8a%91%e5%88%b6%e5%8a%91apg-2575%e4%b8%89%e9%a0%85%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%90%ab1\/22994\"},\"wordCount\":874,\"publisher\":{\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans#organization\"},\"articleSection\":[\"\u672a\u5206\u985e\"],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91-%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5bcl-2%e6%8a%91%e5%88%b6%e5%8a%91apg-2575%e4%b8%89%e9%a0%85%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%90%ab1\/22994\",\"url\":\"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91-%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5bcl-2%e6%8a%91%e5%88%b6%e5%8a%91apg-2575%e4%b8%89%e9%a0%85%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%90%ab1\/22994\",\"name\":\"\u30102024 ASH\u3011 \u4e9e\u76db\u91ab\u85e5Bcl-2\u6291\u5236\u5291APG-2575\u4e09\u9805\u81e8\u5e8a\u7814\u7a76\u5165\u9078\uff0c\u542b1\u9805\u53e3\u982d\u5831\u544a\uff01 - \u9999\u6e2f\u7279\u8a31\u7d93\u71df\",\"isPartOf\":{\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans#website\"},\"datePublished\":\"2024-11-05T23:49:00+00:00\",\"dateModified\":\"2024-11-05T23:49:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91-%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5bcl-2%e6%8a%91%e5%88%b6%e5%8a%91apg-2575%e4%b8%89%e9%a0%85%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%90%ab1\/22994#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91-%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5bcl-2%e6%8a%91%e5%88%b6%e5%8a%91apg-2575%e4%b8%89%e9%a0%85%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%90%ab1\/22994\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91-%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5bcl-2%e6%8a%91%e5%88%b6%e5%8a%91apg-2575%e4%b8%89%e9%a0%85%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%90%ab1\/22994#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9801\",\"item\":\"https:\/\/www.franchise.com.hk\/zh-hans\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u30102024 ASH\u3011 \u4e9e\u76db\u91ab\u85e5Bcl-2\u6291\u5236\u5291APG-2575\u4e09\u9805\u81e8\u5e8a\u7814\u7a76\u5165\u9078\uff0c\u542b1\u9805\u53e3\u982d\u5831\u544a\uff01\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans#website\",\"url\":\"https:\/\/www.franchise.com.hk\/zh-hans\",\"name\":\"\u9999\u6e2f\u7279\u8a31\u7d93\u71df\",\"description\":\"\u9999\u6e2f\u7279\u8a31\u7d93\u71df | Franchise HK\",\"publisher\":{\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.franchise.com.hk\/zh-hans?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans#organization\",\"name\":\"\u9999\u6e2f\u7279\u8a31\u7d93\u71df\",\"url\":\"https:\/\/www.franchise.com.hk\/zh-hans\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans#\/schema\/logo\/image\/\",\"url\":\"https:\/\/i0.wp.com\/www.franchise.com.hk\/wp-content\/uploads\/2022\/05\/cropped-cropped-franchise-logo-02-e1652686851566-2.png?fit=350%2C76&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/www.franchise.com.hk\/wp-content\/uploads\/2022\/05\/cropped-cropped-franchise-logo-02-e1652686851566-2.png?fit=350%2C76&ssl=1\",\"width\":350,\"height\":76,\"caption\":\"\u9999\u6e2f\u7279\u8a31\u7d93\u71df\"},\"image\":{\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30102024 ASH\u3011 \u4e9e\u76db\u91ab\u85e5Bcl-2\u6291\u5236\u5291APG-2575\u4e09\u9805\u81e8\u5e8a\u7814\u7a76\u5165\u9078\uff0c\u542b1\u9805\u53e3\u982d\u5831\u544a\uff01 - \u9999\u6e2f\u7279\u8a31\u7d93\u71df","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91-%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5bcl-2%e6%8a%91%e5%88%b6%e5%8a%91apg-2575%e4%b8%89%e9%a0%85%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%90%ab1\/22994","og_locale":"zh_CN","og_type":"article","og_title":"\u30102024 ASH\u3011 \u4e9e\u76db\u91ab\u85e5Bcl-2\u6291\u5236\u5291APG-2575\u4e09\u9805\u81e8\u5e8a\u7814\u7a76\u5165\u9078\uff0c\u542b1\u9805\u53e3\u982d\u5831\u544a\uff01 - \u9999\u6e2f\u7279\u8a31\u7d93\u71df","og_description":"\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde2024\u5e7411\u67086\u65e5 \/\u7f8e\u901a\u793e\/ &#8212;\u00a0\u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u4f48\uff0c\u516c\u53f8\u91cd\u9ede\u54c1\u7a2eAPG-2575\uff08Lisaftoclax\uff09\u5171\u67093\u9805\u81e8\u5e8a\u9032\u5c55\u7372\u9078\u7b2c66\u5c46\u7f8e\u570b\u8840\u6db2\u5b78\u6703\uff08American Society of Hematology\uff0cASH\uff09\u5e74\u6703\uff0c\u5176\u4e2d\u4e00\u9805\u7372\u53e3\u982d\u5831\u544a\u3002\u9019\u662f\u8a72\u54c1\u7a2e\u7684\u81e8\u5e8a\u9032\u5c55\u9023\u7e8c\u7b2c3\u5e74\u5165\u9078ASH\u5e74\u6703\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u4eca\u5e74\u516c\u53f8\u56db\u500b\u54c1\u7a2e\uff08\u8010\u7acb\u514b\u3001APG-2575\u3001APG-2449\u3001APG-591 ... \u4e86\u89e3\u8a73\u60c5","og_url":"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91-%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5bcl-2%e6%8a%91%e5%88%b6%e5%8a%91apg-2575%e4%b8%89%e9%a0%85%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%90%ab1\/22994","og_site_name":"\u9999\u6e2f\u7279\u8a31\u7d93\u71df","article_published_time":"2024-11-05T23:49:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"4 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91-%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5bcl-2%e6%8a%91%e5%88%b6%e5%8a%91apg-2575%e4%b8%89%e9%a0%85%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%90%ab1\/22994#article","isPartOf":{"@id":"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91-%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5bcl-2%e6%8a%91%e5%88%b6%e5%8a%91apg-2575%e4%b8%89%e9%a0%85%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%90%ab1\/22994"},"author":{"name":"","@id":""},"headline":"\u30102024 ASH\u3011 \u4e9e\u76db\u91ab\u85e5Bcl-2\u6291\u5236\u5291APG-2575\u4e09\u9805\u81e8\u5e8a\u7814\u7a76\u5165\u9078\uff0c\u542b1\u9805\u53e3\u982d\u5831\u544a\uff01","datePublished":"2024-11-05T23:49:00+00:00","dateModified":"2024-11-05T23:49:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91-%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5bcl-2%e6%8a%91%e5%88%b6%e5%8a%91apg-2575%e4%b8%89%e9%a0%85%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%90%ab1\/22994"},"wordCount":874,"publisher":{"@id":"https:\/\/www.franchise.com.hk\/zh-hans#organization"},"articleSection":["\u672a\u5206\u985e"],"inLanguage":"zh-Hans"},{"@type":"WebPage","@id":"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91-%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5bcl-2%e6%8a%91%e5%88%b6%e5%8a%91apg-2575%e4%b8%89%e9%a0%85%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%90%ab1\/22994","url":"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91-%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5bcl-2%e6%8a%91%e5%88%b6%e5%8a%91apg-2575%e4%b8%89%e9%a0%85%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%90%ab1\/22994","name":"\u30102024 ASH\u3011 \u4e9e\u76db\u91ab\u85e5Bcl-2\u6291\u5236\u5291APG-2575\u4e09\u9805\u81e8\u5e8a\u7814\u7a76\u5165\u9078\uff0c\u542b1\u9805\u53e3\u982d\u5831\u544a\uff01 - \u9999\u6e2f\u7279\u8a31\u7d93\u71df","isPartOf":{"@id":"https:\/\/www.franchise.com.hk\/zh-hans#website"},"datePublished":"2024-11-05T23:49:00+00:00","dateModified":"2024-11-05T23:49:00+00:00","breadcrumb":{"@id":"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91-%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5bcl-2%e6%8a%91%e5%88%b6%e5%8a%91apg-2575%e4%b8%89%e9%a0%85%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%90%ab1\/22994#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91-%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5bcl-2%e6%8a%91%e5%88%b6%e5%8a%91apg-2575%e4%b8%89%e9%a0%85%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%90%ab1\/22994"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91-%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5bcl-2%e6%8a%91%e5%88%b6%e5%8a%91apg-2575%e4%b8%89%e9%a0%85%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8c%e5%90%ab1\/22994#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9801","item":"https:\/\/www.franchise.com.hk\/zh-hans"},{"@type":"ListItem","position":2,"name":"\u30102024 ASH\u3011 \u4e9e\u76db\u91ab\u85e5Bcl-2\u6291\u5236\u5291APG-2575\u4e09\u9805\u81e8\u5e8a\u7814\u7a76\u5165\u9078\uff0c\u542b1\u9805\u53e3\u982d\u5831\u544a\uff01"}]},{"@type":"WebSite","@id":"https:\/\/www.franchise.com.hk\/zh-hans#website","url":"https:\/\/www.franchise.com.hk\/zh-hans","name":"\u9999\u6e2f\u7279\u8a31\u7d93\u71df","description":"\u9999\u6e2f\u7279\u8a31\u7d93\u71df | Franchise HK","publisher":{"@id":"https:\/\/www.franchise.com.hk\/zh-hans#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.franchise.com.hk\/zh-hans?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/www.franchise.com.hk\/zh-hans#organization","name":"\u9999\u6e2f\u7279\u8a31\u7d93\u71df","url":"https:\/\/www.franchise.com.hk\/zh-hans","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/www.franchise.com.hk\/zh-hans#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/www.franchise.com.hk\/wp-content\/uploads\/2022\/05\/cropped-cropped-franchise-logo-02-e1652686851566-2.png?fit=350%2C76&ssl=1","contentUrl":"https:\/\/i0.wp.com\/www.franchise.com.hk\/wp-content\/uploads\/2022\/05\/cropped-cropped-franchise-logo-02-e1652686851566-2.png?fit=350%2C76&ssl=1","width":350,"height":76,"caption":"\u9999\u6e2f\u7279\u8a31\u7d93\u71df"},"image":{"@id":"https:\/\/www.franchise.com.hk\/zh-hans#\/schema\/logo\/image\/"}}]}},"jetpack_featured_media_url":"https:\/\/i0.wp.com\/www.franchise.com.hk\/wp-content\/uploads\/2024\/11\/Ascentage_Pharma_Logo-BR28lu.jpeg?fit=597%2C115&ssl=1","_links":{"self":[{"href":"https:\/\/www.franchise.com.hk\/zh-hans\/wp-json\/wp\/v2\/posts\/22994"}],"collection":[{"href":"https:\/\/www.franchise.com.hk\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.franchise.com.hk\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.franchise.com.hk\/zh-hans\/wp-json\/wp\/v2\/comments?post=22994"}],"version-history":[{"count":0,"href":"https:\/\/www.franchise.com.hk\/zh-hans\/wp-json\/wp\/v2\/posts\/22994\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.franchise.com.hk\/zh-hans\/wp-json\/wp\/v2\/media\/22995"}],"wp:attachment":[{"href":"https:\/\/www.franchise.com.hk\/zh-hans\/wp-json\/wp\/v2\/media?parent=22994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.franchise.com.hk\/zh-hans\/wp-json\/wp\/v2\/categories?post=22994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.franchise.com.hk\/zh-hans\/wp-json\/wp\/v2\/tags?post=22994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}